Diagnostic value of peripheral blood eosinophils for benign and malignant pulmonary nodule.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
7
11
2023
Statut:
ppublish
Résumé
This retrospective study aims to assess the diagnostic utility of peripheral blood eosinophil counts in distinguishing between benign and malignant pulmonary nodules (PNs) prior to surgical intervention. We involved patients presenting with PNs measuring ≤30 mm as the primary CT imaging finding prior to surgical procedures at the General Hospital of Northern Theater Command in Shenyang, China, during the period spanning 2021 to 2022. Multivariable logistic regression analysis and receiver operator characteristic curve analysis, along with area under the curve (AUC) calculations, were used to determine the diagnostic value of eosinophil. A total of 361 patients with PN were included, consisting of 135 with benign PN and 226 with malignant PN. Multivariable logistic regression analysis showed that eosinophil percentage (OR = 1.909, 95% CI: 1.323-2.844, P < .001), absolute eosinophil value (OR = 0.001, 95% CI: 0.000-0.452, P = .033), tumor diameter (OR = 0.918, 95% CI: 0.877-0.959, P < .001), nodule type (OR = 0.227, 95% CI: 0.125-0.400, P < .001), sex (OR = 2.577, 95% CI: 1.554-4.329, P < .001), and age (OR = 0.967, 95% CI: 0.945-0.989, P = .004) were independently associated with malignant PN. The diagnostic value of regression model (AUC [95% CI]: 0.775 [0.725-0.825]; sensitivity: 74.3%; specificity: 71.1%) was superior to eosinophil percentage (AUC [95% CI]: 0.616 [0.556-0.677]; specificity: 66.8%; specificity: 51.1%) (Delong test: P < .001). Peripheral blood eosinophil percentage might be useful for early malignant PN diagnosis, and combining that with other characteristics might improve the diagnostic performance.
Identifiants
pubmed: 37932999
doi: 10.1097/MD.0000000000035936
pii: 00005792-202311030-00031
pmc: PMC10627640
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e35936Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394:1145–58.
Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:412–41.
de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382:503–13.
Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007;178:4222–9.
Grisaru-Tal S, Itan M, Klion AD, et al. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20:594–607.
Steel JL, Kim KH, Dew MA, et al. Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. J Pain Symptom Manage. 2010;39:859–71.
Walter R, Joller-Jemelka HI, Salomon F. Metastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels. Exp Hematol. 2002;30:1–2.
Pandit R, Scholnik A, Wulfekuhler L, et al. Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome. Am J Hematol. 2007;82:234–7.
Sakkal S, Miller S, Apostolopoulos V, et al. Eosinophils in cancer: favourable or unfavourable? Curr Med Chem. 2016;23:650–66.
Isaacson NH, Rapoport P. Eosinophilia in malignant tumors; its significance. Ann Intern Med. 1946;25:893–902.
Wang Z, Chen B, Fu Y, et al. Eosinophilia and lung cancer: analysis from Real-World Data and Mendelian Randomization Study. Front Med (Lausanne). 2022;9:830754.
Wei W, Kaiyi L, Yanfang Y, et al. Value of blood eosinophils in the diagnosis of benign and malignant pulmonary nodules. J Med Inf. 2022;35:99–102.
Steinbach KH, Schick P, Trepel F, et al. Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood. Blut. 1979;39:27–38.
Hong SG, Sato N, Legrand F, et al. Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration. Blood. 2020;136:2667–78.
Sibille A, Corhay JL, Louis R, et al. Eosinophils and lung cancer: from bench to bedside. Int J Mol Sci . 2022;23:5066.
Legrand F, Driss V, Delbeke M, et al. Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol. 2010;185:7443–51.
Chusid MJ. Eosinophils: friends or foes? J Allergy Clin Immunol Pract. 2018;6:1439–44.
Carretero R, Sektioglu IM, Garbi N, et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16:609–17.
Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med. 2003;197:387–93.
Wu X, Wang C, Li H, et al. Circulating white blood cells and lung function impairment: the observational studies and Mendelian randomization analysis. Ann Med. 2021;53:1118–28.